Buckner FS, Waters NC, Avery VM. Recent highlights in anti-protozoan drug development and resistance research. Int J Parasitol Drugs Drug Resist. 2012 ;2:230-5. PMID: 24533285.
• ScienceDirect
Buckner FS, Bahia MT, Suryadevara PK, White KL, Shackleford DM, Chennamaneni NK, et al. Pharmacological characterization, structural studies, and in vivo activity of anti-chagas disease lead compounds derived from tipifarnib. Antimicrob Agents Chemother. 2012; 56(9): 4914-21.
• PubMed Abstract
Shibata S, Gillespie JR, Kelley AM, Napuli AJ, Zhang Z, Kovzun KV, Pefley RM, Lam J, Zucker FH, Van Voorhis WC, Merritt EA, Hol WG, Verlinde CL, Fan E, Buckner FS. Selective inhibitors of methionyl-tRNA synthetase have potent activity against Trypanosoma brucei Infection in Mice. Antimicrob Agents Chemother. 2011; 55(5): 1982-9.
• PubMed Abstract
Kraus JM, Verlinde CLMJ, Karimi M, Lepesheva GI, Gelb MH, Buckner FS. Rational modification of a candidate cancer drug for use against Chagas disease. J Med Chem. 2009; 52(6): 1639-47.
• PubMed Abstract
Buckner FS, Wilson AJ. Colorimetric assay for screening compounds against Leishmania amastigotes grown in macrophages. Am J Trop Med Hyg. 2005; 72(5): 600-5.
• PubMed Abstract
Buckner F, Yokoyama K, Lockman J, et al. A class of sterol 14-demethylase inhibitors as anti-Trypanosoma cruzi agents. Proc Natl Acad Sci U S A. 2003; 100(25):15149-53.
• PubMed Abstract